<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T07:38:27Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:10230/12425" metadataPrefix="qdc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:10230/12425</identifier><datestamp>2025-12-24T08:52:47Z</datestamp><setSpec>com_2072_6</setSpec><setSpec>col_2072_452952</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
   <dc:title>Multi-receptor binding profile of clozapine and olanzapine: a structural study based on the new beta (2) adrenergic receptor template</dc:title>
   <dc:creator>López Muñoz, Laura</dc:creator>
   <dc:creator>Pastor Maeso, Manuel</dc:creator>
   <dc:creator>Sanz, Ferran</dc:creator>
   <dc:creator>Selent, Jana</dc:creator>
   <dc:subject>Serotonina</dc:subject>
   <dc:subject>Esquizofrènia -- Quimioteràpia</dc:subject>
   <dc:subject>Esquizofrènia</dc:subject>
   <dcterms:abstract>Schizophrenia is a devastating mental disorder that has a large/nimpact on the quality of life for those who are afflicted and is/nvery costly for families and society.[1] Although the etiology of/nschizophrenia is still unknown and no cure has yet been/nfound, it is treatable, and pharmacological therapy often produces/nsatisfactory results. Among the various antipsychotic/ndrugs in use, clozapine is widely recognized as one ofthe/nmost clinically effective agents, even if it elicits significant side/neffects such as metabolic disorders and agranulocytosis. Clozapine/nand the closely related compound olanzapine are good/nexamples ofdrug s with a complex multi-receptor profile ;[2]/nthey have affinities toward serotonin, dopamine, a adrenergic,/nmuscarinic, and histamine receptors, among others.</dcterms:abstract>
   <dcterms:issued>2011-07-27T08:27:56Z</dcterms:issued>
   <dcterms:issued>2011-07-27T08:27:56Z</dcterms:issued>
   <dcterms:issued>2008</dcterms:issued>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:relation>ChemMedChem. 2008;3(8):1194-8</dc:relation>
   <dc:rights>© 2008 Wiley-VCH Verlag GmbH&amp;amp; Co. KGaA, Weinheim</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:publisher>Wiley-Blackwell</dc:publisher>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>